Related Experiment Videos
Genetic alterations in ERBB2-amplified breast carcinomas
1Laboratory of Cancer Genetics, University and University Hospital of Tampere, Finland.
Summary
ERBB2 gene amplification in breast cancer is linked to more chromosomal alterations. These genetic differences may explain varied responses to therapies and predict immunotherapy effectiveness.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- ERBB2 (ErbB2) oncogene amplification is a key target for breast cancer therapies and predicts chemotherapy response.
- Understanding genetic alterations associated with ERBB2 amplification is crucial for refining treatment strategies.
Purpose of the Study:
- To define chromosome alterations associated with ERBB2 amplification in breast cancer.
- To correlate ERBB2 status with the overall number of genetic events and specific chromosomal aberrations.
- To assess the concordance of different methods for detecting ERBB2 amplification and overexpression.
Main Methods:
- Comparative Genomic Hybridization (CGH) to identify chromosomal alterations.
- Fluorescence In Situ Hybridization (FISH) to validate ERBB2 gene amplification.
- Immunohistochemistry (IHC) to detect ERBB2 protein expression.
Main Results:
- ERBB2-amplified tumors exhibited significantly more chromosomal alterations (11.8-12.7) compared to non-amplified tumors (5.6-7.0).
- ERBB2 positivity correlated with a higher total number of genetic events.
- Increased losses of 18q and gains of 20q were observed in ERBB2-positive tumors. High concordance (82-90%) was found between FISH, IHC, and CGH methods.
Conclusions:
- Breast tumors with ERBB2 overexpression or amplification are genetically distinct from ERBB2-negative tumors.
- These genetic differences may underlie altered responses to adjuvant therapies.
- The distinct genetic profile of ERBB2-positive tumors may predict responsiveness to ERBB2-directed immunotherapies.